Treatment
Empagliflozin clinical trials
We’re tracking 87 recruiting studies that include Empagliflozin, each written for real people, not researchers, below.
Recruiting studies
- NCT06435858RecruitingPhase 2
SGLT2 inhibitor for calcium and magnesium in ADPKD
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help control calcium and magnesium levels in people with a genetic kidney disease called ADPKD. The goal is to see if it improves kidney health over a short period.
Zurich, Canton of ZurichAges 18–75 - NCT06473844Recruiting
SGLT2 inhibitors for adults with sepsis
This trial tests whether a type of diabetes medicine (SGLT2 inhibitors) can help adults with sepsis, a life-threatening response to infection. If you have new-onset sepsis and can take oral medicine, you may be eligible.
Hong Kong, Hong KongAges 18 years+ - NCT06528405RecruitingPhase 2
SGLT2 inhibitor study for acute kidney disease patients
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
TaipeiAges 18–80 - NCT06570473RecruitingPhase 2
RV failure treatment trial for pulmonary hypertension patients
This trial is testing two heart medications, empagliflozin and ranolazine, to see if they can improve right heart function in people with pulmonary hypertension and right ventricular failure. Participants will monitor their symptoms using a smartphone or tablet.
Calgary, AlbertaAges 18 years+ - NCT06613854RecruitingPhase 4
Early combination therapy for type 2 diabetes
This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.
LjubljanaAges 18–70 - NCT06625073RecruitingPhase 4
SGLT2i for heart transplant recipients
This trial is testing a medication called SGLT2i (a type of diabetes drug that also helps the heart and kidneys) in people who have received a heart transplant. It aims to see if this drug can improve health after transplant.
Palo Alto, CaliforniaAges 18 years+ - NCT06642623RecruitingPhase 4
Study on heart and kidney health in type 2 diabetes
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
SeoulAges 19 years+ - NCT06745063RecruitingPhase 2
Study of a diabetes drug to reduce artery stiffness in veterans with obesity
This trial tests whether an SGLT2 inhibitor (a type of diabetes medication) can help reduce stiffness in the arteries of veterans who have obesity. If you are a veteran aged 30-60 with a BMI of 30-45 and have stiffer arteries than expected for your age, this study might be an option.
Columbia, MissouriAges 30–60 - NCT06846411RecruitingPhase 4
Empagliflozin in newly untreated type 2 diabetes
This trial tests a medication called empagliflozin (a type 2 diabetes pill) to see how well it works in people with type 2 diabetes who have not taken any diabetes drugs for at least 8 weeks. If you qualify, you may receive the study drug and help researchers learn more about managing blood sugar.
SeongnamAges 20 years+ - NCT07023172Recruiting
Study of Proline Plus Empagliflozin for Type 2 Diabetes
This study is testing a new medication called Proline Plus Empagliflozin to see how well it works for people with type 2 diabetes. It is for people who are starting this medication for the first time.
Xinyang, HenanAges 18 years+ - NCT07055282RecruitingEarly Phase 1
SGLT2 inhibitor for kidney stone prevention
This trial tests if a diabetes medication (SGLT2i) can help prevent calcium kidney stones. Researchers want to see if it changes the way your urine absorbs and processes minerals.
Chicago, IllinoisAges 18–70 - NCT07214818RecruitingPhase 2/Phase 3
SGLT2 Inhibitors for Adult Primary Nephrotic Syndrome
This trial tests whether SGLT2 inhibitors (a type of diabetes medicine) can help adults with primary nephrotic syndrome, a kidney disease that causes protein leakage and swelling. It aims to see if the drug can protect kidney function and reduce protein loss.
Al Mansurah, Dakahlia GovernorateAges 18 years+ - NCT07304817RecruitingPhase 2
Comparing two heart and kidney medicines in heart failure
This study tests if a new medicine (vicadrostat) works differently than an older one (spironolactone) in people with heart failure or heart disease and reduced kidney function. It aims to understand how they affect proteins in the blood and kidney blood flow.
Groningen, Provincie GroningenAges 18 years+ - NCT07065357Enrolling by invitationPhase 3
A study on a diabetes drug for metabolic syndrome
This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.
Hong KongAges 18–85 - NCT06519448Enrolling by invitation
Testing a pill for non-alcoholic fatty liver disease
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
PragueAges 18–75
Common questions
- Are there clinical trials studying Empagliflozin?
- Yes. Clin2 currently lists 87 recruiting studies that include Empagliflozin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Empagliflozin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Empagliflozin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Empagliflozin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.